Asset 1

Gentest® Blood Cancer Colony Forming Cell (CFC) Assay Service

Assess drug efficacy against blood cancer progenitor cells.

Discovery’s Gentest® blood cancer CFC assay services evaluate and rank the effectiveness of your drug candidates at inhibiting blood cancer stem and progenitor cell expansion.

We incubate diseased cells with your test compound(s) in a semi-solid, methylcellulose-based medium and we then assess cultures for changes in the number of cancer progenitor-derived colonies. We can also test your drug in a standard CFC assay to look for off-target toxicity to healthy donor progenitor cells.

Blood Cancer Drug Efficacy CFC Assays Performed by Blood Cell Biology Experts

Advantages:

Typical Diseases Include:

Featured Resources

Hematopoietic Colony Forming Cell (CFC) Assay

The preclinical screening method that helps clients eliminate bad players earlier in the drug development process. White Paper

Colony Forming Cell Assays Predict Compound Induced Toxicities

Colony Forming Cell assays can predict compound induced toxicities including neutropenia, thrombocytopenia, anemia and lymphotoxicity. Video

ECVAM Validated Assay

This in vitro assay has been validated by ECVAM (European Centre for the Validation of Alternative Methods) and correlates well with clinical neutropenia for many drug classes. Protocol

Contact Us Today

Quick Links

Technologies

Development and Clinical
Trial Solutions